+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cerebral Infarction Treatment Market Size, Share and Trends Analysis Report by Type (Chemotherapy), Drug Class (Oral), Distribution Channel, and Region 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • September 2024
  • Region: Global
  • Grand View Research
  • ID: 6009866
The global cerebral infarction treatment market size is expected to reach USD 20.5 billion by 2030 and is projected to grow at a CAGR of 7.3%. The growing prevalence of ischemic strokes, driven by an aging global population and increasing rates of lifestyle-related risk factors such as hypertension and diabetes, is a key factor in the expansion of the cerebral infarction treatment market.

According to a study published by the National Library of Medicine in March 2023, hemorrhagic stroke accounts for 10.0% to 20.0% of all strokes annually. The incidence varies significantly by region, with 8.0%-15.0% in the U.S., the UK, and Australia, and 18.0% to 24.0% in Japan and Korea. The rate of hemorrhagic stroke is notably higher in low- and middle-income countries, and among Asians. Furthermore, while stroke incidence is higher in men and increases with age, the global burden of hemorrhagic stroke is rising, particularly in African and Asian countries. Effective management of hypertension has been shown to reduce the incidence of intracerebral hemorrhage (ICH), though the fatality rate remains a concern, ranging from 25.0% to 30.0% in high-income countries and 30% to 48% in lower-income regions, highlighting disparities in critical care efficacy.

Technological advancements are significantly enhancing the treatment landscape for cerebral infarction. Innovations in thrombolytic therapies, such as tissue plasminogen activators (tPA), and development of mechanical thrombectomy devices have markedly improved patient outcomes. Moreover, the integration of artificial intelligence (AI) into diagnostic and treatment processes is revolutionizing stroke care. AI-driven algorithms now play a crucial role in predicting stroke risk and tailoring treatment strategies, which helps in personalizing care and improving overall efficacy. These advancements are not only improving the precision of treatments but also contributing to the broader adoption of advanced therapeutic options. Combined with increased investment in research and development, these technological strides are expected to drive significant growth in the cerebral infarction treatment market.

Cerebral Infarction Treatment Market Report Highlights

  • In 2023, the ischemic stroke segment held the largest share of 78.6% due to its high prevalence, technological advancements, and growing awareness of early intervention
  • The tissue plasminogen activators (tPA) segment secured the largest revenue share of 39.7% in 2023, driven by its proven efficacy, widespread use, and crucial role in treating ischemic strokes
  • In 2023, the hospital pharmacies segment dominated the cerebral infarction treatment market, capturing a substantial revenue share of 63.6%

The leading players in the Cerebral Infarction Treatment market include:

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Amneal Pharmaceuticals LLC
  • Sanofi
  • Abbott Laboratories
  • Johnson & Johnson
  • Bristol-Myers Squibb

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug Class
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Drug Class
2.2.3. Distribution Channel
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Cerebral Infarction Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Prevalence Cerebrovascular Diseases
3.2.1.2. Advancements In Medical Technology
3.2.1.3. Aging Global Population
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Treatment and Devices
3.2.2.2. Strict Regulatory Approvals
3.3. Cerebral Infarction Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Cerebral Infarction Treatment Market: Treatment Estimates & Trend Analysis
4.1. Global Cerebral Infarction Treatment Market: Treatment Dashboard
4.2. Global Cerebral Infarction Treatment Market: Treatment Movement Analysis
4.3. Global Cerebral Infarction Treatment Market by Treatment , Revenue
4.4. Ischemic Stroke
4.4.1. Ischemic stroke market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Hemorrhagic stroke
4.5.1. Hemorrhagic stroke market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Cerebral Infarction Treatment Market: Drug Class Estimates & Trend Analysis
5.1. Global Cerebral Infarction Treatment Market: Drug Class Dashboard
5.2. Global Cerebral Infarction Treatment Market: Drug Class Movement Analysis
5.3. Global Cerebral Infarction Treatment Market Estimates and Forecasts, By Drug Class, Revenue (USD Million)
5.4. Tissue Plasminogen Activators
5.4.1. Tissue Plasminogen Activators market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Anticoagulants
5.5.1. Anticoagulants market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Antiplatelets
5.6.1. Antiplatelets market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Anticoagulants
5.7.1. Anticoagulants market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Others
5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Cerebral Infarction Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. Global Cerebral Infarction Treatment Market: Distribution Channel Dashboard
6.2. Global Cerebral Infarction Treatment Market: Distribution Channel Movement Analysis
6.3. Global Cerebral Infarction Treatment Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Cerebral Infarction Treatment Market: Regional Estimates & Trend Analysis by Treatment, Drug Class, and Distribution Channel
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Vendor Landscape
8.2.1. List of key distributors and channel partners
8.2.2. Key company market share analysis, 2023
8.2.3. Amgen Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Pfizer Inc.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Novartis AG
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Amneal Pharmaceuticals LLC
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Sanofi
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Abbott Laboratories
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Johnson & Johnson
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Bristol-Myers Squibb
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
List of Tables
Table 1 List Of Abbreviation
Table 2 North America Cerebral Infarction Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 3 North America Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 4 North America Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 5 North America Cerebral Infarction Treatment Market, Distribution Channel, 2018 - 2030 (USD Million)
Table 6 U.S. Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 7 U.S. Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 8 U.S. Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 9 Canada Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 10 Canada Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 11 Canada Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Mexico Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 13 Mexico Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 14 Mexico Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 15 Europe Cerebral Infarction Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 16 Europe Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 17 Europe Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 Europe Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Germany Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 20 Germany Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 21 Germany Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 UK Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 23 UK Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 24 UK Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 France Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 26 France Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 27 France Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Italy Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 29 Italy Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 30 Italy Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Spain Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 32 Spain Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 33 Spain Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Denmark Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 35 Denmark Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 36 Denmark Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Sweden Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 38 Sweden Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 Sweden Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Norway Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 41 Norway Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Norway Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Cerebral Infarction Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 China Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 48 China Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 49 China Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 50 Japan Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 51 Japan Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 52 Japan Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 India Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 54 India Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 55 India Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 56 South Korea Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 57 South Korea Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 58 South Korea Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Australia Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 60 Australia Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 61 Australia Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Thailand Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 63 Thailand Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 64 Thailand Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 65 Latin America Cerebral Infarction Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 66 Latin America Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 67 Latin America Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 68 Latin America Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Brazil Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 70 Brazil Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 71 Brazil Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 72 Argentina Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 73 Argentina Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 74 Argentina Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 75 MEA Cerebral Infarction Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 76 MEA Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 77 MEA Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 78 MEA Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 79 South Africa Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 80 South Africa Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 81 South Africa Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 85 UAE Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 86 UAE Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 87 UAE Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 88 Kuwait Cerebral Infarction Treatment Market, By Type, 2018 - 2030 (USD Million)
Table 89 Kuwait Cerebral Infarction Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
Table 90 Kuwait Cerebral Infarction Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Cerebral Infarction Treatment Market: Market Outlook
Fig. 14 Cerebral Infarction Treatment Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Cerebral Infarction Treatment Market Driver Impact
Fig. 18 Cerebral Infarction Treatment Market Restraint Impact
Fig. 19 Cerebral Infarction Treatment Market Strategic Initiatives Analysis
Fig. 20 Cerebral Infarction Treatment Market: Treatment Movement Analysis
Fig. 21 Cerebral Infarction Treatment Market: Treatment Outlook and Key Takeaways
Fig. 22 Ischemic Stroke market estimates and forecast, 2018 - 2030
Fig. 23 Hemorrhagic Stroke market estimates and forecast, 2018 - 2030
Fig. 24 Cerebral Infarction Treatment Market: Drug Class Movement Analysis
Fig. 25 Cerebral Infarction Treatment Market: Drug Class Outlook and Key Takeaways
Fig. 26 Tissue Plasminogen Activators market estimates and forecast, 2018 - 2030
Fig. 27 Anticoagulants market estimates and forecast, 2018 - 2030
Fig. 28 Antiplatelets market estimates and forecast, 2018 - 2030
Fig. 29 Anticonvulsants market estimates and forecast, 2018 - 2030
Fig. 30 Others market estimates and forecast, 2018 - 2030
Fig. 31 Cerebral Infarction Treatment Market: Distribution Channel Movement Analysis
Fig. 32 Cerebral Infarction Treatment Market: Distribution Channel Outlook and Key Takeaways
Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030
Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030
Fig. 35 Other market estimates and forecast, 2018 - 2030
Fig. 36 Global Cerebral Infarction Treatment Market: Regional Movement Analysis
Fig. 37 Global Cerebral Infarction Treatment Market: Regional Outlook and Key Takeaways
Fig. 38 Global Cerebral Infarction Treatment market share and leading players
Fig. 39 North America, by country
Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 U.S. key country dynamics
Fig. 42 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Canada key country dynamics
Fig. 44 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Mexico key country dynamics
Fig. 46 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 UK key country dynamics
Fig. 49 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Germany key country dynamics
Fig. 51 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 France key country dynamics
Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Italy key country dynamics
Fig. 55 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Spain key country dynamics
Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Denmark key country dynamics
Fig. 59 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Sweden key country dynamics
Fig. 61 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Norway key country dynamics
Fig. 63 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 China key country dynamics
Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Japan key country dynamics
Fig. 68 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 India key country dynamics
Fig. 70 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Thailand key country dynamics
Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 South Korea key country dynamics
Fig. 74 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Australia key country dynamics
Fig. 76 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Brazil key country dynamics
Fig. 79 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Argentina key country dynamics
Fig. 81 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 South Africa key country dynamics
Fig. 84 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia key country dynamics
Fig. 86 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 UAE key country dynamics
Fig. 88 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Kuwait key country dynamics
Fig. 90 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Market share of key market players - Cerebral Infarction Treatment market

Companies Mentioned

The leading players in the Cerebral Infarction Treatment market include:
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Amneal Pharmaceuticals LLC
  • Sanofi
  • Abbott Laboratories
  • Johnson & Johnson
  • Bristol-Myers Squibb

Methodology

Loading
LOADING...

Table Information